<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930900</url>
  </required_header>
  <id_info>
    <org_study_id>EPI 014</org_study_id>
    <nct_id>NCT04930900</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection</brief_title>
  <official_title>A Two-Treatment, Sequential, Crossover Study of the Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection (Infectious Rhinitis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARS Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARS Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, single-dose, two-period study that will consist of a combined screening&#xD;
      and baseline period and an open-label treatment period. Subjects will be enrolled when they&#xD;
      experience an Upper Respiratory Tract Infection with nasal congestion and edema.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 4, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the bioavailability (Cmax) of ARS-1 after intranasal administration</measure>
    <time_frame>Day -1 to Day 30</time_frame>
    <description>Blood samples will be collected to measure plasma concentrations of adrenaline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the bioavailability (AUC0-t) of ARS-1 after intranasal administration</measure>
    <time_frame>Day -1 to Day 30</time_frame>
    <description>Blood samples will be collected to measure plasma concentrations of adrenaline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the bioavailability (tmax) of ARS-1 after intranasal administration</measure>
    <time_frame>Day -1 to Day 30</time_frame>
    <description>Blood samples will be collected to measure plasma concentrations of adrenaline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Upper Respiratory Tract Infection</condition>
  <arm_group>
    <arm_group_label>ARS-1 with URTI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARS-1 with URTI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARS-1 without URTI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARS-1 without URTI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARS-1 with URTI</intervention_name>
    <description>ARS-1</description>
    <arm_group_label>ARS-1 with URTI</arm_group_label>
    <other_name>Adrenaline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARS-1 without URTI</intervention_name>
    <description>ARS-1 without URTI</description>
    <arm_group_label>ARS-1 without URTI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Treatment Period 1 only, subject has symptoms of an URTI at time of dosing based on&#xD;
             the clinical judgement and the positive infectious cause of URTI to be confirmed by&#xD;
             Respiratory Pathogens Panel.&#xD;
&#xD;
          -  Has body weight more than 55 kg for male and 50 kg for female and body mass index&#xD;
             between 18 and 32 kg/m2, inclusive.&#xD;
&#xD;
          -  Has no declared medical history of hypertension and cardiovascular disease in the last&#xD;
             10 years.&#xD;
&#xD;
          -  At screening, has stable vital signs in the following ranges (after 5 minutes of&#xD;
             rest):&#xD;
&#xD;
               -  SBP ≥90 and ≤140 mmHg&#xD;
&#xD;
               -  DBP ≥50 and ≤90 mmHg&#xD;
&#xD;
               -  HR ≥45 and ≤100 beats per minute (bpm)&#xD;
&#xD;
          -  Is a nonsmoker within the previous 2 months (calculated from first dosing) and does&#xD;
             not use tobacco-containing products.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a stated history of clinically significant gastrointestinal, renal, hepatic,&#xD;
             neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or&#xD;
             cardiovascular disease or any other condition which, in the opinion of the&#xD;
             Investigator, would jeopardize the safety of the subject or impact the validity of the&#xD;
             study results.&#xD;
&#xD;
          -  Has current or past history of clinically significant asthma or angioedema.&#xD;
&#xD;
          -  Has prior nasal fractures, severe nasal injuries or history of nasal disorders that&#xD;
             could interfere with nasal spray administration.&#xD;
&#xD;
          -  Has any clinically significant medical condition or physical exam (PE) finding as&#xD;
             deemed inappropriate by the Investigator.&#xD;
&#xD;
          -  Has abnormal cardiovascular exam at screening including any prior history of&#xD;
             myocardial infarction or clinically significant abnormal ECG.&#xD;
&#xD;
          -  Subject reports they have had significant traumatic injury, major surgery or open&#xD;
             biopsy within 30 days prior to study screening.&#xD;
&#xD;
          -  Subject reports they have donated blood including platelets or plasma only or had an&#xD;
             acute loss of blood (&gt;50 mL) during the 30 days before study drug administration or&#xD;
             intends to donate blood or blood products within 30 days after the completion of the&#xD;
             study.&#xD;
&#xD;
          -  Has a history (within 12 months before screening) of drug use, or has a positive test&#xD;
             for drugs of abuse at screening or upon admittance to the study center, or has a&#xD;
             stated history of alcohol abuse.&#xD;
&#xD;
          -  Has been on an abnormal diet during the four (4) weeks from Day 0. 10. Has&#xD;
             participated in a clinical trial within 30 days prior to the first dose of study drug.&#xD;
&#xD;
             11. Has had treatment with any adrenaline or noradrenaline containing products within&#xD;
             7 days of Day 0.&#xD;
&#xD;
             12. Has inadequate or difficult venous access that may jeopardize the quality or&#xD;
             timing of the PK samples.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony McGirr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern Beach Clinical Research Pty Ltd,</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarina Tanimoto, M.D.</last_name>
    <phone>858-227-3008</phone>
    <email>sarinat@ars-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anthony McGirr</name>
      <address>
        <city>Brookvale</city>
        <state>New South Wales</state>
        <zip>2100</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthonly McGirr, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

